Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer.

"rna-seq data are available on geo (ncbi) under accession gse234734.; availability of data and materials the rna-seq data underlying this article are available in gene expression omnibus repository at https://www ncbi nlm nih gov/geo/ and can be accessed with gse234734. availability of data and materials the rna-seq data underlying this article are available in gene expression omnibus repository at https://www ncbi nlm nih gov/geo/ and can be accessed with gse234734"

"Declarations Competing interestsOur study highlights the cis-acting regulatory features underlying susceptibility to transcriptional and post-transcriptional variations induced by splicing-targeting drugs; it reveals IR as the prominent pattern induced by both direct (Ind/PlaB) and indirect (THZ531) inhibition of splicing and uncovers the 3’-end mRNA processing as a druggable vulnerability for advanced PC. Competing interests Our study highlights the cis-acting regulatory features underlying susceptibility to transcriptional and post-transcriptional variations induced by splicing-targeting drugs; it reveals IR as the prominent pattern induced by both direct (Ind/PlaB) and indirect (THZ531) inhibition of splicing and uncovers the 3’-end mRNA processing as a druggable vulnerability for advanced PC."

"Funding This work was supported by grants from the Italian Ministry of Health (RF-2016–02363460), the Associazione Italiana Ricerca sul Cancro (AIRC IG23416, MFAG21899, IG27896), PRIN 202224MK8Z and “Ministero della Salute—Ricerca Corrente 2023” to IRCCS Fondazione Policlinico A. Gemelli. We acknowledge the financial support of the Università Cattolica del Sacro Cuore (UCSC) for execution and publication of this study."